Floatz logo

su011248

Targeted Molecular Therapy

First Affiliated Hospital, Sun Yat-Sen UniversityN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Targeted Molecular Therapy cohort.

Asset / SponsorPhaseRating
Rivoceranib
The University of Hong Kong-Shenzhen Hospital
D
LENVATINIB
The University of Hong Kong-Shenzhen Hospital
D
Sorafenib
The University of Hong Kong-Shenzhen Hospital
D

Same molecule, other indications

su011248 is also rated in:

Gastrointestinal Stromal TumorsDormant
BBB
Indicative ·
75 / 100
View asset →
Pancreatic Neuroendocrine TumorDormant
BB
Indicative ·
69 / 100
View asset →
Renal Cell CarcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →